Stephanie Hill, Nick Bleeker, Kyle Hadden, Vinod Jadhav, Tamara Vasiljevik, Gary Brandt, Laura Peterson
Jared Mays, Justin Moyers, Josh McManus, Michael Urban, Adam Duerfeldt, David Hymel, Gurpreet Singh, Heidi Manner, Donna Lubbers, Matthew Axtman, Michael Amolins, Brain Blagg
 |
Michael Amolins graduated in May 2007 from Augustana College in Sioux Falls, SD, with a B.A. in Chemistry and minors in Mathematics and Music. He is now a second-year graduate student and Self Fellow working towards a Ph.D. in the Blagg lab. Currently, Michael's project involves the synthesis and evaluation of natural product analogues as Hsp90 inhibitors. mamolins@ku.edu |
 |
Matthew Axtman graduated from Valley City State University in North Dakota earning a B.S. in Chemistry, Health Science and Biology Education with a minor in Athletic Coaching. He is currently a second year graduate student in Dr. Blagg's laboratory. His current project involves making small molecule inhibitors which target the N-terminus of Hsp 90. maxtman@ku.edu |
 |
Gary E. Brandt earned his B.S. in chemistry from Georgia State University in the fall of 2005. He joined the Blagg Laboratory in the Spring of 2007. Gary is currently working on the total synthesis of a natural product, which inhibits F1Fo ATP synthase, and is conducting SAR on Gedunin, a natural product recently found to inhibit HSP90. Gary is a Self Fellow. gebrandt@ku.edu |
 |
James Clark graduated from Southern Utah University in Cedar City, UT where he received a B.S. in Chemistry in 2007. He is a second year graduate student and joined Dr. Blagg's research group during the Spring of 2008. His current project involves the synthesis of small molecule inhibitors targeting the N-terminus of the molecular chaperone, Hsp90. jclarkny@ku.edu |
 |
Alison Donnelly is a third-year graduate student who earned her B.S. in Chemistry and B.A. in Spanish from Case Western Reserve University in Cleveland, OH in spring, 2006. Since joining the Blagg lab in fall, 2006, she has been working on a research project that involves the synthesis and evaluation of novel C-terminal Hsp90 inhibitors based on the novobiocin scaffold. adonnelly@ku.edu |
 |
Adam Duerfeldt received his Bachelors degree in chemistry from Central College in Pella, Iowa and subsequently joined the Blagg laboratory as a graduate student. Currently, Adam is working on the synthesis of chimeric molecules of geldanamycin and radicicol as N-terminal inhibitors of Hsp90. Adam is a Self fellow. aduerf@ku.edu |
 |
Kyle Hadden received his Ph.D. from the Medical University of South Carolina in 2004 where he worked on the synthesis and evaluation of centrally active peptides. After completion of postdoctoral training at the University of Wisconsin in the Department of Biochemistry, Kyle joined the Blagg laboratory in August of 2005. His current project includes the development of Hsp90 assays for high-throughput screening, optimization of small molecule HTS leads as Hsp90 inhibitors, and the synthesis of chimeric analogues of geldanamycin and radicicol. Kyle is a NIH/KUMC postdoctoral fellow. haddenmk@ku.edu |
 |
Stephanie Hill is currently a senior at The University of Kansas majoring in Chemistry and Biochemistry. She is a K-INBRE Scholarship recipient as well as a Goldwater Scholar. Stephanie is working on the synthesis of small molecule inhibitors of Hsp90. steph09@ku.edu |
 |
David Hymel graduated from Louisiana State University in May 2008 with a B.S. in Chemistry and a Biological Science minor. He is currently a first year Ph.D. student working in the Blagg research group. His current project involves the synthesis and evaluation of natural products and their analogues as Hsp90 inhibitors. dhymel3@ku.edu |
 |
Vinod Jadhav received his Ph.D. from the Technical University of Munich, Germany in December 2005, where he worked on molecular recognition based on Guanidinium receptors under the supervision of Prof. Dr. Franz P. Schmidtchen. In January 2008, he joined the Blagg laboratory as a postdoctoral researcher and is currently working on the synthesis of geldanamycin analogs as N-terminal inhibitors of Hsp90. vinodjadhav1977@gmail.com |
 |
Amit Kudalev performed his doctoral research at Memorial University, Canada (Jan. 2004-Aug. 2008) under the supervision of Prof. Graham J. Bodwell. During his Ph.D. he worked on inverse electron demand Diels-Alder reactions of coumarins-fused dienes. He joined the Blagg laboratory in September 2008 as a postdoctoral researcher. His current project involves the design and synthesis of C- and N-terminal inhibitors of the molecular chaperone, Hsp90. amit.kudale@hotmail.com |
 |
Yuanming Lu received his Ph.D. from the University of Fudan in China in 2001, where he worked on molecular pharmacology and toxicology. After the completion of postdoctoral training at the University of Tokushima in the Department of Molecular biology and Biochemistry in Japan, he joined the Blagg laboratory in July of 2007. His current project includes the development of Hsp90 assays for high-throughput screening and characterization of small molecule HTS leads as Hsp90 inhibitors. lu650920@ku.edu |
 |
Donna J. Lubbers received her B.S. degree from Saint Mary's College at Notre Dame in May 2005. Donna joined the Blagg Lab group in January 2006 and is currently in her third year of the masters program. Her projects include synthesis and SAR studies as well as molecular modeling and docking studies of C-terminal Hsp90 inhibitors. Donna is a Self fellow. donnaj@ku.edu |
 |
Heidi Manner is a junior at The University of Kansas. She is majoring in Exercise Science with an emphasis on physical therapy and a minor in French. She joined the Blagg laboratory as an administrative assistant in January 2008. Hsp90admin@ku.edu |
 |
Jared Mays received his Ph.D. in Pharmaceutical Sciences from the University of Wisconsin - Madison in 2007, where he worked on the development of prodrug histone deacetylase (HDAC) inhibitors under the advisership of Dr. Scott Rajski. In June 2007, he joined the Blagg laboratory as a postdoctoral researcher and is currently working on the synthesis of Hsp90 C-terminal inhibitors based on the novobiocin scaffold. Email: jmays@ku.edu |
 |
Joshua McManus received his PhD in 2007 from Murdoch University, where he worked on the synthesis of benzopyranquinones and naphthopyranquinones under the supervision of Professor Robin Giles. In October 2007 he joined the Blagg laboratory as a postdoctoral researcher and is currently preparing a combinatorial library of novobiocin analogues. jdmc@ku.edu |
 |
John Mihelcic completed his Ph.D. from Washington University in St. Louis, where he studied oxidative cyclization reactions and developed the first enantioselective total synthesis of (+)-Alliacol A, a naturally occurring antibiotic, under the direction of Dr. Kevin Moeller. He then completed a post-doctoral position at Covidien, conducting process research on a total synthesis of opiate analgesics. His work as a medicinal chemist at Locus Pharmaceuticals focused on the synthesis of highly novel p38 MAP kinase inhibitors. jm67jm@gmail.com |
 |
Justin Moyers is currently a junior at The University of Kansas majoring in Chemistry. In January 2008, he joined the Blagg lab and is currently working on rational drug design focused on the development for new Hsp90 inhibitors. jazzjm@ku.edu |
 |
Laura Peterson graduated in May 2007 from the University of Colorado at Colorado Springs with a B.S. in chemistry. She is currently a second-year graduate student working towards her Ph.D. working in the Blagg lab. Her current project involves the synthesis and evaluation of natural products and their analogues as Hsp90 inhibitors. lbp@ku.edu |
 |
Kusuma Bhaskar Reddy received his Ph. D from the Indian Institute of Chemical Technology (IICT), Hyderabad, India in March 2007, where he worked on the formal total synthesis of polyketide macrolide antibiotic Bafilomycin A1 and total synthesis of ?-hydroxy ?-lactones, such as prelactone B, V, E, epi-prelactone V, E under the supervision of Dr. J. S. Yadav. He then worked as a post-doctoral fellow in the group of Prof. Marco A. Ciufolini at the University of British Columbia, Vancouver, Canada. In August 2008, he joined the Blagg laboratory as a post-doctoral research scholar and he is currently working on the synthesis of novobiocin analogues as C-terminal inhibitors of HSP90. kusumabr@gmail.com |
 |
Gurpreet Singh is a first year graduate student in medicinal chemistry. He recieved his Bachelor's and Master's in Chemistry from Guru Nanak Dev University, Amritsar, India. Before coming to KU, he worked as a medicinal chemist in Discovery Research in Dr Reddy's Laboratories in Hyderabad, India. gpsingh@ku.edu |
 |
Michael J. Urban received his B.S. in Biology and B.A. in Chemistry from Benedictine College in Atchison, KS, in 2003. After serving four years active duty as an officer in the U.S. Army, Mike joined the Medicinal Chemistry Department as a graduate student in June 2007 and the Blagg group in January 2008. His current project entails a collaborative study with Dr. Rick T. Dobrowsky (Pharmacology and Toxicology), aimed at elucidation of the mechanism that Hsp90 inhibitors exhibit for neuroprotection. mjurban@ku.edu |
 |
Tamara Vasiljevik graduated in May 2007 from Dickinson State University in Dickinson, ND, with a B.S. in both Chemistry and Biology. Upon graduation from DSU, she was employed at Novartis Pharameuticals, OTC division in Lincoln, NE, where she worked for the Analytical development department. She is now a first-year graduate student working towards a Ph.D. and rotating in the Blagg's lab. Currently, Tammi's project involves the synthesis of dimeric small molecules and their antimicrobial activity. tamara11sk@ku.edu |
 |
Huiping Zhaoreceived his PhD from Kansas State University in 2008 where he worked on the bio-based materials and total synthesis of natural product. He joined the Blagg laboratory as a postdoctoral researcher in June 2008 and is currently working on the synthesis of novobiocin analogues as C-terminal inhibitors of Hsp90. hpzhao@ku.edu |
Dr. Brian S. J. Blagg
